title: Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.
abstract: Stored plasma specimens from 164 participants in the ANRS 138 trial were analyzed to determine interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP), and D-dimer levels at baseline and weeks 24 and 48. These virologically suppressed, treatment-experienced patients were randomly assigned to undergo an immediate switch (IS) or a deferred switch (DS; at week 24) from an enfuvirtide-based antiretroviral therapy (ART) regimen to a raltegravir-based regimen. At week 24, a significant decrease from baseline was observed in the IS arm, compared with the DS arm, for IL-6 level (-30% vs +10%; P < .002), hsCRP level (-46% vs +15%; P < .0001), and D-dimer level (-40% vs +6%; P < .0001). At week 48, there was a reproducible decrease in levels of all biomarkers in the DS arm.
authors.affiliation: Department of Infectious Diseases, AP-HP, Hôpital Saint Louis, University of Paris Diderot Paris, France.
authors.forename: Erika F
authors.initials: EF
authors.lastname: Silva
authors.forename: Isabelle
authors.initials: I
authors.lastname: Charreau
authors.forename: Bernard
authors.initials: B
authors.lastname: Gourmel
authors.forename: Samia
authors.initials: S
authors.lastname: Mourah
authors.forename: Issa
authors.initials: I
authors.lastname: Kalidi
authors.forename: Brigitte
authors.initials: B
authors.lastname: Guillon
authors.forename: Nathalie
authors.initials: N
authors.lastname: De Castro
authors.forename: François
authors.initials: F
authors.lastname: Caron
authors.forename: Josephine
authors.initials: J
authors.lastname: Braun
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Molina
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood*; D001777:Blood Coagulation / Q000187:drug effects*; D002097:C-Reactive Protein / Q000032:analysis; D018791:CD4 Lymphocyte Count; D000077560:Enfuvirtide; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000821:virology; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D000068898:Raltegravir Potassium; D013048:Specimen Handling; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D015700:HIV Envelope Protein gp41; D015850:Interleukin-6; D010446:Peptide Fragments; D011760:Pyrrolidinones; D012367:RNA, Viral; C036309:fibrin fragment D; D000077560:Enfuvirtide; D000068898:Raltegravir Potassium; D002097:C-Reactive Protein
keywords: CRP; D-dimer; HIV; IL-6; biomarkers; enfuvirtide; raltegravir; switch